Approved for TEVIMBRA (tislelizumab-jsgr) is a PD-1 blocking antibody indicated: in combination with platinum-containing chemotherapy for first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC); as a single agent for adults with unresectable or metastatic ESCC after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor; and for…
Loading full data from Know Your Drugs Institute…